The Board of Better Capital PCC Limited has received an update from the General Partner of the Better Capital Funds ahead of the release of the Interim Report to 30 September 2016. 2012 Cell NAV may fall by 14% Everest is expected to close FY16 with positive EBITDA better than prior year albeit, significantly below […]
Workspace’s EPRA net asset value per share was down 0.9% over the six months ended 30 September 2016, falling from 923p to 915p. Adjusted underlying earnings per share rose 15.2% to 14.4p as net rental income was up 6% to £38.0m. The interim dividend has been upped by 40% to 6.8p. Net initial yields shifted from 5% […]
JPMorgan Japan Smaller Companies Trust reports that its NAV return for the half year ended 30th September 2016, was 14.1% (15.4% adjusting for the effect of the subscription shares), versus 22.5% for the benchmark. The share price total return was 16.5%. The Board was notified during the period of Naohiro Ozawa’s decision to resign from […]
Henderson International Income Trust very marginally underperformed its benchmark over the year to 31 August 2016. The total return on the net asset value was 26.9%. The return on the ordinary share price was 24.0%. These returns compare to a total return of 27.2% in the MSCI World (ex UK) Index (sterling adjusted). They also announced a dividend […]
HgCapital, the Manager of HgCapital Trust has announced that is has made an investment in Evaluate Group, a London-headquartered provider of commercial intelligence to the global life sciences industry. The terms of this transaction have not been disclosed. HgCapital Trust plc will invest in Evaluate, alongside other institutional clients of HgCapital, who will participate through […]
Electra Private Equity has announced proposals to return up to £200m to shareholders via a tender offer. The company says that Morgan Stanley & Co. International plc or to act as principal and a circular dated 8 November 2016, containing the full terms and conditions, together with a Tender Form and details of a General […]
Fidelity Special Values just failed to keep pace with its benchmark over the year to 31 August 2016, delivering a NAV return of 9.9% against 11.7% for the index. The total dividend for the year is 3.7p, 10.4% higher than last year. The discount widened from 2.0% at the start of the reporting year to 10.0% […]
Over the six months to the end of September, both Scottish Mortgage’s net asset value (NAV) and price per share rose by 25% on a total return basis; for context, the FTSE All World Index rose by 18% over the same period. All three of these figures were favourably influenced by the falls in the pound against […]
BACIT plans to expand its investment policy and grow its assets under management with a couple of deals. This will nudge the fund towards becoming more of a life sciences company. BACIT is hoping to acquire Syncona LLP, a limited partnership vehicle founded by Wellcome Trust. this has an existing portfolio of life science investments. The […]
International Biotechnology Trust outperformed the Nasdaq Biotech Index over the year to the end of August 2016 as the fund’s NAV return was -1.7% against -3.8% for the index. Unfortunately, the discount widened from 5.7% to 13.5% and therefore the return to shareholders was -9.8%. Quoted portfolio The quoted portfolio outperformed the NBI by 1.1% in the […]
